Asset profile
LNK01004
Small molecule
Evidence outlook · lead readout
NCT07071610 · Atopic Dermatitis
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT07071610: The trial randomized 75 participants to two LNK01004 doses or a vehicle control and used quadruple blinding. Its primary endpoint was the clinical EASI score, but because no primary-outcome results or statistical comparison are available, the findings remain unknown.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.